COMPANY PROFILE

Lycera

Biopharmaceutical company that seeks to uncover new small molecule therapies for the treatment of autoimmune diseases and cancer

Ann Arbor, United StatesFounded 2006Biotech & Life Sciences

Valuation $100–250M Last recorded · 2015

Headcount <100 Current team size

Total funding $50–100M Disclosed equity funding

Unlock exact values

About Lycera

Lycera is a biopharmaceutical company focused on developing next-generation drugs to address autoimmune diseases and cancer by modulating the immune system. The company operates in the healthcare and pharmaceutical markets, primarily serving patients suffering from immune system dysregulation. Lycera's business model revolves around advancing clinical and preclinical programs, particularly through the development of RORgamma agonists, which enhance CAR T cell anti-tumor activity and persistence. Revenue is generated through the development and potential commercialization of these innovative therapeutics. The company's integrated research teams, comprising medicinal chemists, immunologists, and physicians, are dedicated to transforming proprietary research findings into novel compounds with significant therapeutic potential.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2006
Headquarters: Ann Arbor, United States
Employees: 18
Open positions: None listed
Dealroom signal: 59.4/100
Industry: Health
Sub-industry: Pharmaceutical, BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Oncology, Autoimmune, Spinout, Biotech and Pharma, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website X

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

8 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES BOther financing	Jun 2015	$30M	$120M	Undisclosed	—
DEBTDebt	Apr 2014	$4M	—	Undisclosed	—

Showing the latest 2 of 8 recorded eventsBook a demo for the full funding history →

Growth signals

Lycera website traffic

Latest recorded traffic for Lycera is 280 monthly website visits, up 27.3% over the last three months. Lycera's team grew 0% over the past year.

Latest monthly visits280 3-month web change+27.3% 1-year team growth0%

Monthly website visitsApr 2016–May 2024

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
BTBright Peak TherapeuticsDeveloping next-generation immunotherapies, focusing on the treatment of cancer and autoimmune diseases	Basel, Switzerland	Operational	36	$232M	$535M
PBPrincipia BioPharmaBiopharmaceutical company focused on oncology and autoimmune disease	San Francisco, United States	Acquired
ASAltheia ScienceA gene therapy company	Milan, Italy	Operational
ABAdicet BioA biotechnology company discovering and developing first-in-class allogeneic gamma delta CAR t cell therapies for cancer	Redwood City, United States	Operational
ITImCheck TherapeuticsDesigning and developing a new generation of immunotherapy antibodies	Marseille, France	Acquired
ATAtrecaPrecision Therapies from the Immune Response	San Carlos, United States	Operational
BBBullet BiotechnologyBullet Technology \| Active Immunotherapy for Cancer & Autoimmune Diseases	Menlo Park, United States	Operational
XEXencorDevelops superior monoclonal antibody therapeutics to treat autoimmune disorders, asthma, allergic diseases and cancer	Monrovia, United States	Operational